Abstract
Background Prenatal care provides pregnant women with repeated opportunities for prevention, screening and diagnosis that have no current extension to future fathers. It also contributes to women’s general better access to health. The goal of PARTAGE study was to evaluate the level and determinants of adherence to a prenatal prevention consultation dedicated to men.
Methods Between January 2021 and April 2022, we conducted a monocentric interventional study in Montreuil hospital. We assessed the acceptance of a prenatal prevention consultation newly offered to every future father, through their pregnant partner’s prior consent to provide their contact details.
Results 3,038 women provided contact information used to reach the fathers; effective contact was established with 2,516 men, of whom 1,333 (53%) came for prenatal prevention consultation. Immigrant men were more likely to come than French-born men (56% versus 49%, p < 0·001), and the more they faced social hardship, the more likely they were to accept the offer. In multivariate analysis, men born in Subsaharan Africa and Asia were twice as likely to attend the consultation as those born in Europe or North America.
Conclusion Acceptance of this new offer was high. Moreover, this consultation was perceived by vulnerable immigrant men as an opportunity to integrate a healthcare system they would otherwise remain deprived of.
Trial Registration https://classic.clinicaltrials.gov/ct2/show/NCT05085717
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05085717
Clinical Protocols
https://www.ceped.org/IMG/pdf/protocole_partage_anglais.pdf
Funding Statement
This study was funded by the French National Agency for Research on AIDS,viral hepatitis, tuberculosis and emerging disease (ANRS-MIE)and by the French Society Against AIDS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee Comite de Protection des Personnes (French Personnal Data Protection Comittee) Nord Ouest II gave two ethical approvals to this work: 21.01.19.44753 and 21.05022.944753 authorizing a substantial modification (increase in the number of inclusions).The Comite de Protection des Personnes (CPP)Nord Ouest II is a dedicated ethics oversight body.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Membership for the PARTAGE Study Group is provided in the Aknowledgments section
The title was changed, the abstract was improved.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- MQ
- Maternal Questionnaire
- SMA
- State Medical Assistance (Aide Médicale de l’Etat in French)
- FPPC
- Father’s Prenatal Prevention Consultation
- CI
- Confidence Interval OR: Odd Ratio
